Bluejay Diagnostics, Inc.
BJDXNasdaqHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $249,040 | — | — |
| Operating income | −$7.0M | −$7.2M | −$10.3M | −$9.3M | −$3.2M | −$1.2M |
| Net income | −$6.8M | −$7.7M | −$10.0M | −$9.3M | −$3.5M | −$1.2M |
| Total assets | $7.1M | $6.7M | $4.9M | $13.5M | $21.0M | $1.5M |
| Total liabilities | $1.1M | $927,924 | $2.0M | $2.0M | $637,162 | $1.8M |
| Equity | $6.0M | $5.7M | $2.9M | $11.5M | $20.4M | −$4.2M |
| EPS (diluted) | $-15.25 | $-456.75 | $-3631.48 | $-9.22 | $-0.41 | — |
| Shares out. | 554,012 | 2.7M | 20.5M | 20.2M | 20.1M | 3.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −114.6%
- Return on assets
- −96.2%
- Return on capital (ROCE)
- −115.9%
- Liabilities / assets
- 16.1%
- Debt / equity
- 0.19×
- Book value / share
- $10.79
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -16.09distress
- Accruals / assets
- −11.2%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Wurth Douglas ClarkDirector | Mar 14, 2026 | Buy | 12,500 | $2.00 |
| Dey IndranilOfficer — President and CEO | Mar 14, 2026 | Buy | 12,500 | $2.00 |
| Chase Donald RDirector | Mar 14, 2026 | Buy | 12,500 | $2.00 |
| Zeidman Fred SDirector | Mar 14, 2026 | Buy | 12,500 | $2.00 |
| Dey SvetlanaDirector | Mar 14, 2026 | Buy | 12,500 | $2.00 |
| Dey SvetlanaDirector | Dec 13, 2023 | Buy | 500 | $3.07 |
| Dey IndranilOfficer — President and CEO | Dec 13, 2023 | Buy | 500 | $3.27 |
| Dey IndranilOfficer — President and CEO | Mar 27, 2023 | Grant | 8,000 | $0.44 |
| Dey SvetlanaDirector | Mar 24, 2023 | Grant | 10,000 | $0.44 |
| Gemignani Gary GDirector | Feb 1, 2023 | Grant | 27,500 | $0.44 |
| Chase Donald RDirector | Feb 1, 2023 | Grant | 27,500 | $0.44 |
| Dey SvetlanaDirector | Feb 1, 2023 | Grant | 27,500 | $0.44 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 6,757 | 1.0 | -68.5% |
| Apr 30, 2026 | 21,481 | 2.2 | +24.5% |
| Apr 15, 2026 | 17,259 | 1.0 | -59.8% |
| Mar 31, 2026 | 42,958 | 2.1 | -24.6% |
| Mar 13, 2026 | 56,970 | 1.0 | +53.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Regulation FD disclosureApr 7, 2026
- Entered a material agreement · Unregistered equity saleMar 17, 2026
- Regulation FD disclosureMar 16, 2026
- Regulation FD disclosureMar 12, 2026
- Results of operationsMar 6, 2026
- Regulation FD disclosureFeb 20, 2026
- Regulation FD disclosureFeb 18, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- 4STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIESMay 18, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QQUARTERLY REPORTMay 7, 2026
- 8-KCURRENT REPORTMay 7, 2026
- DEF 14APROXY STATEMENTApr 30, 2026
- PRE 14APROXY STATEMENTApr 20, 2026
- 8-KCURRENT REPORTApr 7, 2026
- 8-KCURRENT REPORTMar 17, 2026
- 8-KCURRENT REPORTMar 16, 2026
- 8-KCURRENT REPORTMar 12, 2026
- SCHEDULE 13DMar 11, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.